US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

61.45

+0.52160.86%

Volume:192.56K

Turnover:11.76M

Market Cap:271.61M

PE:20.10

High:62.12

Open:61.37

Low:60.40

Close:60.93

52wk High:64.10

52wk Low:39.36

Shares:4.42M

Float Shares:4.42M

Volume Ratio:6.46

T/O Rate:4.36%

Dividend:1.53

Dividend Rate:2.48%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Axsome Therapeutics Q2 Revenue Rises on Auvelity Growth

Axsome Therapeutics Shares Down 8.4% Premarket After Q2 Revenue Miss

THOMSON REUTERS

Axsome Q2 FY26 Net Loss Widens to $51.3 Million; Net Product Revenue Climbs 46% to $218.4 Million Year over Year

Axsome Therapeutics Q2 Net Income USD -51.314 Million

Axsome Therapeutics Q2 EPS USD -0.99

THOMSON REUTERS

Axsome Therapeutics Q2 Operating Expenses USD 268.021 Million

THOMSON REUTERS

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS

Roivant Sciences Ltd : Citigroup Raises Target Price to $46 from $42

THOMSON REUTERS

BeOne Medicines partners with Revolution Medicines for clinical development

BeOne Medicines Teams with Revolution Medicines on RAS Cancer Drug Development, Asia Rights Deal

Beone Medicines - Receives Exclusive Rights to Four Revolution Medicines Assets in Select Asian Markets

THOMSON REUTERS

Beone Medicines - to Fund and Conduct Global Phase 3 Study for Ras(on) Inhibitor

THOMSON REUTERS

Beone Medicines - Revolution Medicines Eligible for Milestone Payments and Tiered Royalties in Partnered Region

THOMSON REUTERS

Revolution Medicines, Inc. : JP Morgan Raises Target Price to $227 from $205

THOMSON REUTERS

Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?

Simply Wall St.

Axsome Therapeutics (AXSM) Could Be 25% Undervalued As CNS Pipeline Hopes Build

Simply Wall St.

Huadong Medicine Subsidiary Secures EU MDR CE Certification for Medical Device

Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)

RBC Capital Remains a Buy on GH Research (GHRS)

Axsome CEO Herriot Tabuteau Disposes of USD 10.54 Million in Common Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/PTH/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":61.45,"timestamp":1788379200000,"preClose":60.9284,"halted":0,"volume":192563,"delay":0,"changeRate":0.008560868166569275,"floatShares":4420000,"shares":4420000,"eps":3.057033,"marketStatus":"Pre-Mkt","change":0.5216,"latestTime":"09-03 08:10:05 EDT","open":61.3732,"high":62.12,"low":60.4,"amount":11760338.478839999,"amplitude":0.02823,"askPrice":69.83,"askSize":100,"bidPrice":54.21,"bidSize":100,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788442200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":61.45,"sharesOutstanding":2480000,"nav":60.94509,"aum":270596199.6,"dividendRate":0.024845,"bidAskSpread":0.002104,"postHourTrading":{"tag":"盘后","latestPrice":61.45,"preClose":61.45,"latestTime":"19:30 EDT","volume":11,"amount":675.4001,"timestamp":1788391802992,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":6.461672143855177,"impliedVol":0.116,"impliedVolPercentile":0.4462},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4420000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":6.461672143855177,"shares":4420000,"dividePrice":1.5267,"high":62.12,"amplitude":0.02823,"preClose":60.9284,"low":60.4,"week52Low":39.36,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":61.45,"eps":3.057033,"divideRate":0.024845,"volume":192563,"delay":0,"ttmEps":3.057033,"open":61.3732,"prevYearClose":49.701,"prevWeekClose":61.0661,"prevMonthClose":60.7941,"prevQuarterClose":59.76,"fiveDayClose":63.629,"twentyDayClose":60.0964,"sixtyDayClose":48.9492},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658938415","title":"Axsome Therapeutics Q2 Revenue Rises on Auvelity Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2658938415","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658938415?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:10","pubTimestamp":1786360249,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics Q2 revenue rises on AUVELITY growthOverviewUS biopharmaceutical firm's Q2 revenue grew 46% yr/yr but missed analyst expectationsNet loss for Q2 widened slightly compared to last ye","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N44709M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4007","LU0566484027.USD","BK4505","BK4539","TMCI","ANIP","AXSM","BK4139","LU1559883803.SGD","GYRE","BK4585","LU2324357040.USD","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658893819","title":"Axsome Therapeutics Shares Down 8.4% Premarket After Q2 Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658893819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658893819?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:08","pubTimestamp":1786360128,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL4N4470MO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4505","AXSM","BK4585","LU2324357040.USD","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658381179","title":"Axsome Q2 FY26 Net Loss Widens to $51.3 Million; Net Product Revenue Climbs 46% to $218.4 Million Year over Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2658381179","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658381179?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:08","pubTimestamp":1786360116,"startTime":"0","endTime":"0","summary":"Axsome Q2 FY26 net loss widens to $51.3 million; net product revenue climbs 46% to $218.4 million year over yearAxsome posted 2Q 2026 net product revenue of $218.4 million, up 46% year over year.Net l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL4b4sNn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","BK4585","BK4007","BK4505","PTH","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658383679","title":"Axsome Therapeutics Q2 Net Income USD -51.314 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658383679","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658383679?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:01","pubTimestamp":1786359662,"startTime":"0","endTime":"0","summary":"BRIEF-Axsome Therapeutics Q2 Net Income USD -51.314 MillionAug 10 (Reuters) - Axsome Therapeutics Q2 pretax profit USD -51.186 million.Q2 operating income USD -49.646 millionQ2 operating expenses USD 268.021 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nPLX24BRB4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2324357040.USD","PTH","BK4505","BK4585","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658938554","title":"Axsome Therapeutics Q2 EPS USD -0.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2658938554","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658938554?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:00","pubTimestamp":1786359602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nPLX24BRB4:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2324357040.USD","PTH","BK4007","AXSM","BK4505","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658777980","title":"Axsome Therapeutics Q2 Operating Expenses USD 268.021 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658777980","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658777980?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:00","pubTimestamp":1786359602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nPLX24BRB4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4585","BK4007","PTH","LU2324357040.USD","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658798005","title":"Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658798005","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658798005?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:00","pubTimestamp":1786359602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUA9MN6XK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AXSM","LU2324357040.USD","BK4505","PTH","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658987522","title":"Roivant Sciences Ltd : Citigroup Raises Target Price to $46 from $42","url":"https://stock-news.laohu8.com/highlight/detail?id=2658987522","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658987522?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:15","pubTimestamp":1786356924,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4470K6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658110987","title":"BeOne Medicines partners with Revolution Medicines for clinical development","url":"https://stock-news.laohu8.com/highlight/detail?id=2658110987","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658110987?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:15","pubTimestamp":1786356922,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) and Revolution Medicines (RVMD) announced a multi-part collaboration including: a clinical collaboration to evaluate drug com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-partners-with-revolution-medicines-for-clinical-development-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-partners-with-revolution-medicines-for-clinical-development-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B2B36J28.USD","PTH","BK4139","RVMD","LU0109394709.USD","CANC","IE0009355771.USD","BK4585","BK4588","IDNA","IE00BFTCPJ56.SGD","BBH","IE00BJJMRZ35.SGD","BK4526","IE00B4R5TH58.HKD","LU0889565916.HKD","IE00BJT1NW94.SGD","ONC","LU0320765992.SGD","IE0009354923.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658982220","title":"BeOne Medicines Teams with Revolution Medicines on RAS Cancer Drug Development, Asia Rights Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2658982220","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658982220?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:01","pubTimestamp":1786356092,"startTime":"0","endTime":"0","summary":"BeOne Medicines teams with Revolution Medicines on RAS cancer drug development, Asia rights dealBeOne Medicines AG entered a multi-part collaboration with Revolution Medicines covering clinical develo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL9VYymL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","IE00BFTCPJ56.SGD","IE0009354923.USD","IE0002141913.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","CANC","IE00BJT1NW94.SGD","688235","IE00B4R5TH58.HKD","LU0889565916.HKD","BK0239","LU0320765992.SGD","RVMD","IDNA","BBH","IE00B2B36J28.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658982475","title":"Beone Medicines - Receives Exclusive Rights to Four Revolution Medicines Assets in Select Asian Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2658982475","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658982475?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:00","pubTimestamp":1786356000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUA4MKT8N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BFTCPJ56.SGD","LU0109394709.USD","BK4139","IE0002141913.USD","PTH","IE00B2B36J28.USD","IE0009354923.USD","IE00BJJMRZ35.SGD","BK0239","RVMD","LU0889565916.HKD","BBH","IDNA","IE0009355771.USD","IE00BJT1NW94.SGD","LU0320765992.SGD","IE00B4R5TH58.HKD","CANC","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658982449","title":"Beone Medicines - to Fund and Conduct Global Phase 3 Study for Ras(on) Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2658982449","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658982449?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:00","pubTimestamp":1786356000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUA4MKT8N:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBH","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE0009354923.USD","BK4139","IDNA","IE0009355771.USD","LU0889565916.HKD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK0239","RVMD","688235","CANC","IE0002141913.USD","IE00BJT1NW94.SGD","LU0109394709.USD","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658296982","title":"Beone Medicines - Revolution Medicines Eligible for Milestone Payments and Tiered Royalties in Partnered Region","url":"https://stock-news.laohu8.com/highlight/detail?id=2658296982","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658296982?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:00","pubTimestamp":1786356000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUA4MKT8N:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RVMD","IE0002141913.USD","IE00BJT1NW94.SGD","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4139","IDNA","IE00BJJMRZ35.SGD","PTH","688235","CANC","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0109394709.USD","BBH","IE0009354923.USD","BK0239","LU0320765992.SGD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658006076","title":"Revolution Medicines, Inc. : JP Morgan Raises Target Price to $227 from $205","url":"https://stock-news.laohu8.com/highlight/detail?id=2658006076","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658006076?lang=en_us&edition=fundamental","pubTime":"2026-08-10 14:04","pubTimestamp":1786341899,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN447095:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BFTCPJ56.SGD","PTH","CANC","BBH","RVMD","IE0009355771.USD","LU0320765992.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE0009354923.USD","BK4139","IE00BJT1NW94.SGD","IDNA","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658660616","title":"Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658660616","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658660616?lang=en_us&edition=fundamental","pubTime":"2026-08-10 07:38","pubTimestamp":1786318701,"startTime":"0","endTime":"0","summary":"GH Research PLC recently reported second-quarter 2026 results showing a net loss of US$15.15 million, up from US$9.29 million a year earlier, with basic and diluted loss per share from continuing operations rising to US$0.23 from US$0.15.\nFor the first half of 2026, the company’s net loss expanded to US$34.11 million versus US$20.10 million in the prior-year period, highlighting a meaningful increase in cash burn and pressure on its financial profile.\nWe’ll now examine how this widening net...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/is-gh-researchs-rising-loss-per-share-reframing-the-ghrs-cas","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/is-gh-researchs-rising-loss-per-share-reframing-the-ghrs-cas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GNMX","LU0320765992.SGD","LU0109394709.USD","BK4588","BK4007","LFSC","GHRS","GDOC","BK4535","EKG","GH","BK4539","PSIL","LU0889565916.HKD","FFOX","GNOM","PTH","BK4585","HELX","BK4551","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658606133","title":"Axsome Therapeutics (AXSM) Could Be 25% Undervalued As CNS Pipeline Hopes Build","url":"https://stock-news.laohu8.com/highlight/detail?id=2658606133","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658606133?lang=en_us&edition=fundamental","pubTime":"2026-08-10 07:35","pubTimestamp":1786318507,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics event context and recent stock performance\nAxsome Therapeutics (AXSM) continues to draw investor attention as it advances therapies for central nervous system disorders, including approved treatments for depression, excessive daytime sleepiness, and migraine, alongside multiple late stage clinical programs.\nThe stock last closed at US$212.74 on 7 August 2026. Over the past month the share price declined 9%, while the past 3 months show a smaller fall of 1.7%, leaving the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/axsome-therapeutics-axsm-could-be-25-undervalued-as-cns-pipe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/axsome-therapeutics-axsm-could-be-25-undervalued-as-cns-pipe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","BK4505","LU2324357040.USD","PTH","BK4135","BGSX","BK4585","CNS","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145023735","title":"Huadong Medicine Subsidiary Secures EU MDR CE Certification for Medical Device","url":"https://stock-news.laohu8.com/highlight/detail?id=1145023735","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145023735?lang=en_us&edition=fundamental","pubTime":"2026-08-09 16:40","pubTimestamp":1786264814,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. (000963.SZ) announced that its wholly-owned UK subsidiary, Sinclair Pharma Limited (\"Sinclair\"), has obtained EU MDR CE certification for KIO015, a novel injectable...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","09996","BK4109","BK1100","LGHT","159883","PTH","MDEV","HART","BK0132","BK0175","MEDX","IEIH","LU2328871848.SGD","BK4585","LNGR","AGNG","RSPH","BK0183","BK1574","000963","FSXEmain","FESXmain","CE","BK0209","BK1583","BK0188","BK4588","BK0196","PSCM","GDOC","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657567890","title":"Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657567890","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657567890?lang=en_us&edition=fundamental","pubTime":"2026-08-08 22:40","pubTimestamp":1786200025,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and Revolution Medicines (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-spyre-therapeutics-syre-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-spyre-therapeutics-syre-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","IDNA","IE0002141913.USD","CANC","LU0889565916.HKD","IE00BJT1NW94.SGD","PTH","BBH","SYRE","LU0109394709.USD","LU0320765992.SGD","BK4139","IE00BFTCPJ56.SGD","RVMD","IE00BJJMRZ35.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657229326","title":"RBC Capital Remains a Buy on GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657229326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657229326?lang=en_us&edition=fundamental","pubTime":"2026-08-08 09:45","pubTimestamp":1786153544,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research on August 6 and set a price target of $42.00. The company’s shares closed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4196","BK4007","LU0029864427.USD","PTH","GHRS","GNOM","GH","BK4585","LU1267930573.SGD","BK4551","EKG","GNMX","LFSC","FFOX","LU0320765992.SGD","BK4588","PSIL","LU0708994859.HKD","BK4207","BK4535","LU0310800379.SGD","LU0889565916.HKD","GDOC","GSIB","LU0128525929.USD","HELX","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657621762","title":"Axsome CEO Herriot Tabuteau Disposes of USD 10.54 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2657621762","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657621762?lang=en_us&edition=fundamental","pubTime":"2026-08-08 07:00","pubTimestamp":1786143638,"startTime":"0","endTime":"0","summary":"Axsome CEO Herriot Tabuteau disposes of USD 10.54 million in common sharesAxsome Therapeutics CEO Herriot Tabuteau sold 49,664 shares on Aug. 5-6 at weighted average prices of $212.01 and $213.95.Sale","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDLc4nn64:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Axsome CEO Herriot Tabuteau Disposes of USD 10.54 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4505","PTH","AXSM","BK4007","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}